Dr Jacob Adam Mong, DO | |
5680 W Gage St, Boise, ID 83706-1326 | |
(208) 377-3937 | |
(208) 377-9455 |
Full Name | Dr Jacob Adam Mong |
---|---|
Gender | Male |
Speciality | Ophthalmology |
Experience | 13 Years |
Location | 5680 W Gage St, Boise, Idaho |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1346535481 | NPI | - | NPPES |
1346535481 | Medicaid | ID | |
20006959 | Other | ID | MEDICARE PTAN |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207W00000X | Ophthalmology | 1346535481 (Michigan) | Secondary |
207W00000X | Ophthalmology | O-0860 (Idaho) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
St Luke's Regional Medical Center | Boise, ID | Hospital |
Saint Alphonsus Medical Center - Ontario, Inc | Ontario, OR | Hospital |
West Valley Medical Center | Caldwell, ID | Hospital |
Weiser Memorial Hospital | Weiser, ID | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Vision Quest Medical Center Pa | 0547528598 | 5 |
Vision Quest Medical Center Pa | 0547528598 | 5 |
News Archive
Oxygen Biotherapeutics, Inc. today announced that the company has begun distribution for its newly formulated Dermacyte™ Oxygen Concentrate for the beauty and skin care market. The over-the-counter product is a scientifically designed perfluorocarbon concentrate to enhance oxygen delivery to skin.
The U.S. Food and Drug Administration announced today that federal judge Algenon L. Marbley of the Southern District of Ohio has approved a consent decree of permanent injunction against Shamrock Medical Solutions Group, LLC, of Lewis Center, Ohio, and four of its corporate officers and employees for continued drug manufacturing and labeling violations that resulted in the distribution of mislabeled drugs.
The risk for hip fractures among elderly individuals increases during the first 45 days after initiating antihypertensive medication, and significantly so for those who start angiotensin II converting-enzyme inhibitors and beta-adrenergic blockers, report Canadian researchers.
A scalable, mobile phone-based intervention designed to slow weight regain after an initial weight loss had no significant effect on participants' weight, according to a study published this week in PLOS Medicine by Falko Sniehotta from Newcastle University, UK and colleagues.
› Verified 7 days ago
Entity Name | Vision Quest Medical Center, Pa |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1356542542 PECOS PAC ID: 5294622965 Enrollment ID: O20040228000233 |
News Archive
Oxygen Biotherapeutics, Inc. today announced that the company has begun distribution for its newly formulated Dermacyte™ Oxygen Concentrate for the beauty and skin care market. The over-the-counter product is a scientifically designed perfluorocarbon concentrate to enhance oxygen delivery to skin.
The U.S. Food and Drug Administration announced today that federal judge Algenon L. Marbley of the Southern District of Ohio has approved a consent decree of permanent injunction against Shamrock Medical Solutions Group, LLC, of Lewis Center, Ohio, and four of its corporate officers and employees for continued drug manufacturing and labeling violations that resulted in the distribution of mislabeled drugs.
The risk for hip fractures among elderly individuals increases during the first 45 days after initiating antihypertensive medication, and significantly so for those who start angiotensin II converting-enzyme inhibitors and beta-adrenergic blockers, report Canadian researchers.
A scalable, mobile phone-based intervention designed to slow weight regain after an initial weight loss had no significant effect on participants' weight, according to a study published this week in PLOS Medicine by Falko Sniehotta from Newcastle University, UK and colleagues.
› Verified 7 days ago
Entity Name | Vision Quest Medical Center Pa |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1356542542 PECOS PAC ID: 0547528598 Enrollment ID: O20171220000841 |
News Archive
Oxygen Biotherapeutics, Inc. today announced that the company has begun distribution for its newly formulated Dermacyte™ Oxygen Concentrate for the beauty and skin care market. The over-the-counter product is a scientifically designed perfluorocarbon concentrate to enhance oxygen delivery to skin.
The U.S. Food and Drug Administration announced today that federal judge Algenon L. Marbley of the Southern District of Ohio has approved a consent decree of permanent injunction against Shamrock Medical Solutions Group, LLC, of Lewis Center, Ohio, and four of its corporate officers and employees for continued drug manufacturing and labeling violations that resulted in the distribution of mislabeled drugs.
The risk for hip fractures among elderly individuals increases during the first 45 days after initiating antihypertensive medication, and significantly so for those who start angiotensin II converting-enzyme inhibitors and beta-adrenergic blockers, report Canadian researchers.
A scalable, mobile phone-based intervention designed to slow weight regain after an initial weight loss had no significant effect on participants' weight, according to a study published this week in PLOS Medicine by Falko Sniehotta from Newcastle University, UK and colleagues.
› Verified 7 days ago
Entity Name | Maple Grove Eyecare Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1124684485 PECOS PAC ID: 6608101282 Enrollment ID: O20190718002555 |
News Archive
Oxygen Biotherapeutics, Inc. today announced that the company has begun distribution for its newly formulated Dermacyte™ Oxygen Concentrate for the beauty and skin care market. The over-the-counter product is a scientifically designed perfluorocarbon concentrate to enhance oxygen delivery to skin.
The U.S. Food and Drug Administration announced today that federal judge Algenon L. Marbley of the Southern District of Ohio has approved a consent decree of permanent injunction against Shamrock Medical Solutions Group, LLC, of Lewis Center, Ohio, and four of its corporate officers and employees for continued drug manufacturing and labeling violations that resulted in the distribution of mislabeled drugs.
The risk for hip fractures among elderly individuals increases during the first 45 days after initiating antihypertensive medication, and significantly so for those who start angiotensin II converting-enzyme inhibitors and beta-adrenergic blockers, report Canadian researchers.
A scalable, mobile phone-based intervention designed to slow weight regain after an initial weight loss had no significant effect on participants' weight, according to a study published this week in PLOS Medicine by Falko Sniehotta from Newcastle University, UK and colleagues.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Jacob Adam Mong, DO 5680 W Gage St, Boise, ID 83706-1326 Ph: (208) 377-3937 | Dr Jacob Adam Mong, DO 5680 W Gage St, Boise, ID 83706-1326 Ph: (208) 377-3937 |
News Archive
Oxygen Biotherapeutics, Inc. today announced that the company has begun distribution for its newly formulated Dermacyte™ Oxygen Concentrate for the beauty and skin care market. The over-the-counter product is a scientifically designed perfluorocarbon concentrate to enhance oxygen delivery to skin.
The U.S. Food and Drug Administration announced today that federal judge Algenon L. Marbley of the Southern District of Ohio has approved a consent decree of permanent injunction against Shamrock Medical Solutions Group, LLC, of Lewis Center, Ohio, and four of its corporate officers and employees for continued drug manufacturing and labeling violations that resulted in the distribution of mislabeled drugs.
The risk for hip fractures among elderly individuals increases during the first 45 days after initiating antihypertensive medication, and significantly so for those who start angiotensin II converting-enzyme inhibitors and beta-adrenergic blockers, report Canadian researchers.
A scalable, mobile phone-based intervention designed to slow weight regain after an initial weight loss had no significant effect on participants' weight, according to a study published this week in PLOS Medicine by Falko Sniehotta from Newcastle University, UK and colleagues.
› Verified 7 days ago
Dr. Mark J Boerner, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 111 W Main St Ste 200, Boise, ID 83702 Phone: 208-344-3220 Fax: 208-344-0461 | |
James R Swartley, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 222 N 2nd St, Suite 215, Boise, ID 83702 Phone: 208-342-2706 | |
Landon Kelly Grange, M.D. Ophthalmology Medicare: May Accept Medicare Assignments Practice Location: 5680 W Gage St, Boise, ID 83706 Phone: 208-773-3937 Fax: 208-377-3937 | |
Dr. Chad Harman Jackson, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 111 W Main St Ste 200, Boise, ID 83702 Phone: 208-344-3220 Fax: 208-344-0461 | |
Daniel R Brooks, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 222 N 2nd St, Ste 215, Boise, ID 83702 Phone: 208-381-6910 | |
John R Sonntag, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 5680 W Gage St, Boise, ID 83706 Phone: 208-377-3937 Fax: 208-377-9455 | |
Ali Torab Parhiz, M.D Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 901 N Curtis Rd Ste 302, Boise, ID 83706 Phone: 812-424-2020 |